BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 7914749)

  • 1. Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.
    Nüssler V; Pelka-Fleischer R; Zwierzina H; Nerl C; Beckert B; Gullis E; Gieseler F; Bock S; Bartl R; Petrides PE
    Ann Hematol; 1994; 69 Suppl 1():S25-9. PubMed ID: 7914749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression.
    Nüssler V; Gieseler F; Zwierzina H; Gullis E; Pelka-Fleischer R; Diem H; Abenhardt W; Schmitt R; Langenmayer I; Wohlrab A; Kolb HJ; Wilmanns W
    Ann Hematol; 1997 Feb; 74(2):57-64. PubMed ID: 9063374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
    Ries C; Loher F; Zang C; Ismair MG; Petrides PE
    Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis.
    Kuwazuru Y; Yoshimura A; Hanada S; Ichikawa M; Saito T; Uozumi K; Utsunomiya A; Arima T; Akiyama S
    Br J Haematol; 1990 Jan; 74(1):24-9. PubMed ID: 1968762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients.
    Nuessler V; Gullis E; Pelka-Fleischer R; del Valle F; Diem H; Beyerlein S; Zwierzina H; Wilmanns W
    Ann Hematol; 1997; 75(1-2):17-26. PubMed ID: 9322679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein expression in patients with acute leukemia-clinical relevance.
    Nüssler V; Pelka-Fleischer R; Zwierzina H; Nerl C; Beckert B; Gieseler F; Diem H; Ledderose G; Gullis E; Sauer H; Wilmanns W
    Leukemia; 1996 Jul; 10 Suppl 3():S23-S31. PubMed ID: 8656697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarubicin in blastic crisis of chronic myelogenous leukemia.
    Lambertenghi-Deliliers G; Annaloro C; Cortellaro M; Pozzoli E; Oriani A; Polli EE
    Haematologica; 1991; 76(5):406-8. PubMed ID: 1806446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance.
    Kuwazuru Y; Yoshimura A; Hanada S; Utsunomiya A; Makino T; Ishibashi K; Kodama M; Iwahashi M; Arima T; Akiyama S
    Cancer; 1990 Sep; 66(5):868-73. PubMed ID: 1974821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of P-glycoprotein in chronic myelogenous leukaemia patients: expression, activity and correlations with CD34 antigen.
    Turkina AG; Baryshnikov AY; Sedyakhina NP; Folomeshkina SV; Sokolova MA; Choroshco ND; Stavrovskaya AA
    Br J Haematol; 1996 Jan; 92(1):88-96. PubMed ID: 8562416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic myelogenous leukemia with blastic crisis in which expression of P-glycoprotein was associated with resistance to chemotherapy].
    Utsunomiya A; Kuwazuru Y; Chuman Y; Mishige Y; Saito T; Terada A; Iwahashi M; Hanada S; Yoshimura A; Akiyama S
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1915-8. PubMed ID: 1355642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
    Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM
    J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the multidrug resistance-associated protein in myelodysplastic syndromes.
    Poulain S; Lepelley P; Preudhomme C; Cambier N; Cornillon J; Wattel E; Cosson A; Fenaux P
    Br J Haematol; 2000 Sep; 110(3):591-8. PubMed ID: 10997969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
    J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia.
    Wetzler M; Kurzrock R; Estrov Z; Estey E; Talpaz M
    Leuk Res; 1995 Jan; 19(1):23-34. PubMed ID: 7837815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML.
    Elgie AW; Sargent JM; Williamson CJ; Lewandowicz GM; Taylor CG
    Adv Exp Med Biol; 1999; 457():29-33. PubMed ID: 10500777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
    List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
    Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells.
    Lawrence HJ; Sauvageau G; Ahmadi N; Lopez AR; LeBeau MM; Link M; Humphries K; Largman C
    Exp Hematol; 1995 Oct; 23(11):1160-6. PubMed ID: 7556525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An evaluation of the prognostic significance of antigen CD95(Fas/APO-1) expression on the cells of patients with a myelodysplastic syndrome, acute myeloid leukemia and chronic myeloleukemia].
    Polosukhina ER; Kuznetsov SV; Logcheva NP; Zabotina TN; Tenuta MR; Shirin AD; Kaletin GI; Turkina AG; Tsvetaeva NV; Shishkin IuV; Kadagidze ZG; Khoroshko ND; Volkova MA; Baryshnikov AIu
    Ter Arkh; 1998; 70(7):21-5. PubMed ID: 9742630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
    Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P
    Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.